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ABSTRACT
Introduction: ‘REASSURE’ (NCT01377012), a
phase 3 study, evaluated the efficacy and safety
of secukinumab in patients with active
rheumatoid arthritis (RA) who had an
inadequate response to, or intolerance of,
tumor necrosis factor inhibitors
(TNF-inhibitors).
Methods: A total of 637 patients were random-
ized (1:1:1) to receive intravenous secukinumab
10 mg/kg (baseline, weeks 2 and 4) followed by
subcutaneous secukinumab 150 mg or 75 mg
every 4 weeks (starting from week 8) or placebo at
the same dosing schedule. The primary endpoint
was the American College of Rheumatology 20%
improvement criteria (ACR20) at week 24. Other
predefined hierarchical endpoints included
Health Assessment Questionnaire-Disability
Index, van der Heijde modified total Sharp score
(vdH-mTSS) at week 24, and major clinical
response (MCR; continuous 6 month period of
ACR70 response) at 1 year.
Results: The primary efficacy endpoint was met
with both secukinumab dose groups: ACR20
response rate at week 24 was 35.2% for both
secukinumab dose groups (P = 0.0009) vs 19.6%
for placebo. The improvements in secondary
endpoints were greater in the secukinumab dose
groups vs placebo but did not meet statistical
significance. The overall safety profile was sim-
ilar across all treatment groups.
Conclusion: Secukinumab demonstrated effi-
cacy in reducing disease activity over placebo as
measured by ACR20 in patients with active RA
who had an inadequate response to TNF-in-
hibitors. Secukinumab demonstrated a safety
profile similar to other biologics currently
approved for RA.
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic, inflam-
matory, systemic autoimmune disease charac-
terized by symmetric synovitis leading to
cartilage damage and joint destruction, which
may also be complicated by numerous
extra-articular manifestations [1]. Current
treatment for RA with traditional disease mod-
ifying anti-rheumatic drugs (DMARDs) is often
inadequate as these drugs only partially control
established disease, and have many adverse
effects that limit their use [2]. While tumor
necrosis factor inhibitors (TNF-inhibitors) are
the first line biologics used in DMARD failure
patients, 30–40% of patients with established
disease fail to respond to them [2]. Further,
many of those who do initially respond do not
go on to achieve complete remission or lose
response over time [2]. Biologics targeting other
disease driving mechanisms, such as co-stimu-
latory modulators with Cytotoxic T lympho-
cyte—associated antigen 4 Ig
(CTLA-4-immunoglobulin), B cell depletion as
well as interleukin (IL)-6 receptor blockers, are
approved for use in patients for whom TNF-in-
hibitor therapy has failed [3–5].
IL-17A, the key pro-inflammatory cytokine
in the TH17 pathway, is recognized as a key
cytokine in autoimmunity [6]. While its role in
the pathogenesis of RA is not yet fully under-
stood, it has been suggested that it plays a piv-
otal role in both the inflammatory and
destructive joint tissue manifestations of RA
[7–9]. Secukinumab (AIN457), a fully human
monoclonal antibody that neutralizes the
activity of IL-17A, [6] has demonstrated efficacy
in moderate-to-severe psoriasis, psoriatic
arthritis (PsA) and ankylosing spondylitis (AS)
[1, 10–14].
While secukinumab displayed some efficacy
in RA in several phase II trials, the small size of
the trials did not allow for definitive conclu-
sions on the role of IL-17A blockade in RA to be
made [15–18]. Subsequently, three phase 3
studies of secukinumab in RA were initiated;
two assessed the efficacy and safety of secu-
kinumab in comparison with placebo, and the
third compared secukinumab with both placebo
and the active comparator abatacept [19]. Here,
we report, from the phase 3 REASSURE study,
efficacy at week 24 compared with placebo, as
well as the longer term safety of secukinumab in
patients with RA who had an inadequate
response to, or intolerance of, TNF-inhibitors.
METHODS
Study Design
This phase 3 study (ClinicalTrials.gov identifier,
NCT01377012) used a double-blind, random-
ized, parallel-group, placebo-controlled design
to assess the efficacy and safety of secukinumab
in patients with active RA who had an inade-
quate response to, or intolerance of, TNF-in-
hibitors. It included 139 centers in 15 countries.
The core study was conducted over 2 years and
the extension was planned to be conducted for
3 years, however, due to early termination of
the secukinumab RA program, patients
remaining in the trial at the time of termination
were discontinued.
After a 4-week screening period, patients
were randomly assigned (1:1:1) to receive
intravenous (i.v.) secukinumab 10 mg/kg (base-
line, weeks 2 and 4) followed by subcutaneous
(s.c.) secukinumab 150 mg or 75 mg every
4 weeks (starting at week 8) up to week 48, or
placebo on the same i.v. and s.c. dosing sched-
ule (Fig. 1).
At week 16, patients on placebo who were
non-responders (response was defined as C 20%
improvement from baseline in both tender and
swollen joint counts) were re-randomized (1:1)
to receive s.c. secukinumab 150 mg
(placebo-secukinumab 150 mg) or 75 mg
(placebo-secukinumab 75 mg) every 4 weeks.
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Patients who were placebo responders at week
16 continued to receive placebo until week 24,
when they were randomized (1:1) to s.c. secu-
kinumab 150 or 75 mg every 4 weeks. Rescue
medication was not allowed until week 24.
However, patients who were deemed to be not
benefiting from the study drug by the investi-
gator, or for any reason on their own accord,
were free to discontinue participation in the
study at any time. Patients who completed the
Fig. 1 Study design
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2 year core study were eligible to enter the
open-label extension study, where all patients
received s.c. secukinumab 150 mg every
4 weeks.
Primary and secondary efficacy data are pre-
sented for the core study (placebo-controlled up
to week 24) up to week 52. Additionally, long-
er-term (104-week) efficacy data are presented.
Safety data are presented for the initial 16-week
period, as well as for the entire study including
the extension, up to last patient last visit (LPLV).
Patients
Patients aged at least 18 years who had been
diagnosed with RA at least 3 months before
screening, and classified using the ACR 2010
classification criteria were eligible for the study.
Patients were required to have active disease at
baseline, defined by C 6/68 tender joints
and C 6/66 swollen joints, and be positive for
either rheumatoid factor or anti-cyclic citrulli-
nated peptides (CCP) antibodies, in combina-
tion with high-sensitivity C-reactive protein
(hsCRP) C 10 mg/L or erythrocyte sedimenta-
tion rate (ESR) C 28 mm/h.
Patients had to have been on at least one
TNF-inhibitor for at least 3 months before ran-
domization and have experienced an inade-
quate response or intolerance. Patients should
also have received methotrexate for at least
3 months, and be on a stable dose for at least
4 weeks, before randomization. Patients taking
systemic corticosteroids or NSAIDs had to be on
a stable dose for at least 4 weeks before ran-
domization. Patients who had been taking
DMARDs other than methotrexate (MTX), or
were on a TNF-inhibitor, underwent an appro-
priate wash-out period prior to randomization.
The major exclusion criteria included RA
patients having functional status class IV
according to the ACR 1991 revised criteria,
ongoing rheumatic or inflammatory joint dis-
eases other than RA, evidence of malignancy or
infection seen on chest X-ray, active tubercu-
losis infection, previous use of biologic
immunomodulating agents except TNF-in-
hibitors, or previous exposure to secukinumab
or other biologic drugs targeting IL-17.
The study was conducted in accordance with
the Declaration of Helsinki, and was approved
by the institutional review boards or indepen-
dent ethics committees. Written informed
consent was provided by all enrolled patients.
Outcomes
The primary objective was to demonstrate that
the efficacy of secukinumab 150 or 75 mg at
week 24 was superior to placebo, based on the
proportion of patients achieving the American
College of Rheumatology 20% improvement
criteria (ACR20 response).
Secondary objectives included in the
pre-defined hierarchical testing strategy were to
demonstrate superiority of secukinumab
150 mg or 75 mg over placebo in terms of
change from baseline in the Health Assessment
Questionnaire-Disability Index (HAQ-DI), van
der Heijde modified total Sharp score
(vdH-mTSS) at week 24 (pooled for both secu-
kinumab dose regimens), and achieving a con-
tinuous six-month period of ACR70 response
(major clinical response; MCR) at week 52.
Additional secondary efficacy endpoints
included change from baseline in joint/bone
damage (radiographic score), erosion and joint
space narrowing, ACR20/50/70 and EULAR
responses, as well as Disease Activity Score 28
(DAS28), DAS28 remission (DAS28\2.6) and
low disease activity (DAS28 B 3.2, using hsCRP),
vs placebo, over time up to week 104.
Safety was assessed throughout the core and
extension periods. All treatment emergent
adverse events (TEAEs), serious AEs (SAEs), lab-
oratory evaluations, immunogenicity
(anti-secukinumab antibodies) were evaluated.
Statistical Analysis
Sample size calculations were performed using
Fisher’s exact test; as two secukinumab regi-
mens were tested against placebo with respect
to the primary endpoint (ACR20 response at
week 24), the type-I-error was split to 2.5%
two-sided for each comparison.
With 210 patients randomized to each
treatment group, this trial had
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approximately[99% power to detect
between-group differences in the primary end-
point, and was also sufficiently powered to
detect between-group differences in the sec-
ondary endpoints, such as changes from base-
line to week 24 in HAQ-DI ([99% power) and
van der Heijde modified total Sharp score
(68%), and MCR at week 52 (88%).
In terms of minimum sample sizes, for 90%
power, and assuming a response rate of 20% in
the placebo regimen, at least 70 patients per
regimen were needed to show a response rate of
50% in the secukinumab regimens.
Analyses of efficacy variables were performed
on all patients who were randomized and to
whom study treatment had been assigned (full
analysis set, FAS). The primary endpoint of
ACR20 at week 24 was analyzed via logistic
regression with treatment as a factor and base-
line body weight as a covariate. Odds ratios and
95% CIs were presented comparing each
secukinumab regimen to placebo. Continuous
variables (e.g. ACR components, HAQ-DI, etc.)
were analyzed using a mixed-effects repeated
measures model (MMRM). As such, single-point
imputation of missing data was not performed.
A predefined hierarchical test was used to pro-
tect the family-wise type I error rate at 5% across
the primary and the ranked secondary
endpoints.
In general, for binary endpoints, data miss-
ing due to patients meeting the criteria for early
escape at week 16 was handled as non-respon-
ders. This was done for all treatment regimens
in order to minimize bias. For continuous end-
points, data collected after the patient switched
to secukinumab was treated as missing for pla-
cebo patients and was analyzed using a
mixed-effects repeated measures model
(MMRM), which is valid under the missing at
random (MAR) assumption. For secukinumab
patients, the actual values were used in the
analysis.
Analyses of safety endpoints were performed
on all patients who received at least one dose of
the study drug during the treatment period
(safety set). Patients were evaluated according to
treatment received. As appropriate, the inci-
dence of AEs was presented per 100 patient
years of exposure.
RESULTS
Patients
In total, 637 patients were randomized to
secukinumab 150 mg (n = 213), secukinumab
75 mg (n = 210) or placebo (n = 214). This study
and its extension were discontinued early, due
to initial results from the direct comparison
with abatacept [19] suggesting no additional
benefit to RA patients with inadequate response
to TNF-inhibitors. Overall, 237 (37.2%) patients
completed 104 weeks of treatment: 81 (38.0% of
those randomized) in the secukinumab 150 mg
group, 76 (36.2% of those randomized) in the
secukinumab 75 mg group, and 80 (37.4% of
those randomized) in the placebo group (sup-
plementary Fig. S1). Of these, 196 (82.7%)
entered the extension study and were treated
with s.c. secukinumab 150 mg (only dose stud-
ied in extension). The main reason for discon-
tinuation other than study termination was lack
of efficacy (106 patients), followed by subject
decision (56 patients). The maximum exposure
time for any secukinumab dose in the study,
including the extension study, was 184 weeks,
with a mean exposure of 604 (SD ± 341.23)
days, and a median exposure of 588 days.
Of the 214 patients randomized to placebo,
190 remained on the study at week 16. Of these,
110 were non-responders at week 16, and 109 of
these were randomized to secukinumab 150 mg
(n = 53) or secukinumab 75 mg (n = 56). Of the
80 placebo responders at week 16, 72 were
randomized at week 24 to secukinumab 150 mg
(n = 34) or secukinumab 75 mg (n = 38).
Patient demographics and baseline charac-
teristics were comparable across the treatment
groups (Table 1). Most patients (C 80% in each
treatment group) were\65 years of age, with
median age ranging from 53.0 (placebo group)
to 54.0 years (both secukinumab treatment
groups). The majority of patients were female
(range 85.0–88.6% in all treatment groups),
were of Caucasian (range 38.6–41.8%) or Asian
(range 31.0–36.7%) origin and weighed\90 kg
(range 85.5–86.7%). The mean BMI was
approximately 27 kg/m2 across all treatment
groups.
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Table 1 Demographics and baseline characteristics
Characteristic Secukinumab 150 mg
(n5 213)
Secukinumab 75 mg
(n5 210)
Placebo
(n5 214)
Age (years), mean (SD) 53.2 (11.6) 53.3 (12.3) 52.2 (11.6)
Female, n (%) 188 (88.3) 186 (88.6) 182 (85.0)
Weight (kg), mean (SD) 67.6 (20.0) 67.5 (18.9) 69.1 (19.8)
Race, n (%)
Caucasian 89 (41.8) 81 (38.6) 84 (39.3)
Black 12 (5.6) 10 (4.8) 7 (3.3)
Asian 66 (31.0) 77 (36.7) 74 (34.6)
Native American 34 (16.0) 30 (14.3) 40 (18.7)
Other 12 (5.6) 11 (5.2) 9 (4.2)
Unknown 0 (0.0) 1 (0.5) 0 (0.0)
Tender 68-joint count, mean (SD) 26.6 (16.2) 26.6 (15.6) 24.7 (15.8)
Swollen 66-joint count, mean (SD) 17.1 (11.0) 17.2 (10.9) 16.4 (11.3)
Duration of RA (years), mean (SD) 9.0 (8.0) 8.4 (8.0) 7.8 (8.0)
HAQ-DI, mean (SD) 1.7 (0.7) 1.7 (0.6) 1.7 (0.6)
Total vdH-mTSS score, mean (SD) 48.1 (51.8) 55.0 (55.3) 57.7 (66.8)
DAS28-CRP 4.9 (0.9) 4.9 (0.9) 4.8 (0.8)
DAS-28-ESR 5.7 (0.9) 5.7 (0.8) 5.6 (0.8)
Positive for RFa, n (%) 200 (93.9) 191 (91.0) 200 (93.5)
Positive for anti-CCP antibodies, n (%) 194 (91.1) 189 (90.0) 194 (90.7)
TNF-naı¨ve patients, n (%) 1 (0.5) 9 (4.3) 5 (2.3)
Prior use of other biologic DMARD,
n (%)b
1 (0.5) 0 (0.0) 1 (0.5)
Use of oral DMARDs at randomization, n (%)
Methotrexate 208 (97.7) 208 (99.0) 210 (98.1)
Leﬂunomide 1 (0.5) 0 (0) 1 (0.5)
Otherc 6 (2.8) 9 (4.3) 15 (7.0)
Systemic glucocorticoids use, n (%) 124 (58.2) 130 (61.9) 126 (58.9)
DAS28 Disease Activity Score in 28 joints, DMARD disease-modifying anti-rheumatic drug, ESR erythrocyte sedimentation
rate, HAQ-DI Health Assessment Questionnaire-Disability Index, IV intravenous, SD standard deviation, vdH-mTSS van
der Heijde modiﬁed total Sharp score, RA rheumatoid arthritis, RF rheumatoid factor, TNF tumor necrosis factor
a Negative was deﬁned as RF\14 U/mL
b Other than TNF-alpha inhibitors
c Other than MTX and Leﬂunomide
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Efficacy
Primary Efficacy Endpoint
The primary endpoint was met by both the
secukinumab groups; 35.2% of patients in the
150 mg group and 35.2% of patients in the 75 mg
group achieved ACR20, compared with 19.6% in
the placebo group (P = 0.0009; Table 2 and
Fig. 2). In both treatment groups, secukinumab
groups had a rapid onset of action, and both
groups demonstrated numerically higher ACR20
response rates than placebo at all time points up
to week 24, with a more pronounced difference
over placebo after week 8 (Fig. 2).
Secondary Efficacy Endpoints Included
in the Pre-defined Hierarchical Testing
Strategy
The first secondary endpoint, HAQ-DI at week
24, was not met by either secukinumab group,
and consequently neither were the remaining
secondary endpoints in the hierarchal analysis.
For HAQ-DI score, LS mean changes from
baseline at week 24 were - 0.35 for both
secukinumab groups, compared with - 0.24 the
placebo group (supplementary Fig. S2). Secu-
kinumab (pooled 150 mg and 75 mg) reduced
numerically the progression of structural dam-
age over 24 weeks; vdH-mTSS was numerically
lower in the pooled secukinumab group com-
pared with the placebo group (treatment com-
parison estimate 0.82; P = 0.0673, unadjusted).
This did not achieve statistical significance in
the testing hierarchy (P = 0.2009, adjusted;
Table 2). Mean changes in vdH-mTSS from
baseline to week 24 were 0.56 and 1.10 in the
secukinumab 150 mg and 75 mg groups,
respectively, and 1.35 in the placebo group.
At week 24, 71.6% and 66.7% of patients in the
secukinumab 150 mg and 75 mg groups, respec-
tively, had no radiographic disease progression
Table 2 Summary of primary and secondary endpoints at weeks 24, 52 and 104
Endpoint, n (%) unless
stated
Week Secukinumab 150 mg
(n5 213)
Secukinumab 75 mg
(n5 210)
Placebo
(n 5 214)
ACR20a 24 75 (35.2)* 74 (35.2)* 42 (19.6)
52 88 (61.5) 75 (57.7) N/A
104 50 (69.4) 50 (74.6) N/A
ACR50a 24 34 (16.0)* 37 (17.6)* 14 (6.5)
52 36 (27.7) 34 (23.8) N/A
104 28 (38.9) 25 (37.3) N/A
ACR70a 24 8 (3.8) 17 (8.1)* 5 (2.3)
52 14 (9.8) 13 (10.0) N/A
104 12 (16.7) 9 (13.4) N/A
HAQ-DIb 24 - 0.4 (0.0) - 0.4 (0.0) - 0.2 (0.1)
52 - 0.4 (0.6) - 0.4 (0.6) N/A
104 - 0.5 (0.7) - 0.5 (0.7) N/A
ACR American College of Rheumatology, CRP C-reactive protein, DAS28 disease activity score in 28 joints, ESR ery-
throcyte sedimentation rate, HAQ-DI Health Assessment Questionnaire-Disability Index, N/A not assessed, SD standard
deviation, SE standard error
a Non-responder imputation data at week 24 and observed data at week 52, n (%)
b Mixed-effect model repeated measures (MMRM) ± SE data at week 24 and observed data ± SD at week 52
* P\0.05 for secukinumab vs placebo
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(change B 0 from baseline in vdH-mTSS), both of
which were numerically higher than the placebo
group (59.0%), as calculated by logistic regression
with evaluable cases in the full analysis set.
MCR rate over the first 52 weeks was 0.9%
[odds ratio (OR) 1.00; P = 1.000, unadjusted]
and 2.4% (OR 2.57; P = 0.2821, unadjusted) for
the secukinumab 150 mg and 75 mg groups,
respectively, compared with 0.9% for the pla-
cebo group (Table 2).
Other Secondary Efficacy Endpoints
Observed ACR20 response rates for both secu-
kinumab groups were stable from week 8 through
week 104. Following a rapid onset of action, with a
numerically higher proportion of patients in both
secukinumab groups achieving the ACR20
response at week 1 compared with the placebo
group. After the placebo controlled period the
observed response rates for secukinumab were
sustained.
Observed ACR50 responses at week 24 were
numerically greater for both secukinumab
groups [secukinumab 150 mg, 17.6% (OR 2.69;
P = 0.0031, unadjusted) and secukinumab
75 mg, 16.0% (OR 3.03; P = 0.0008, unad-
justed)], compared with placebo (6.5%; Table 2).
Progression in vdH-mTSS over time was lower
in patients treated with secukinumab 150 mg
than those treated with the 75 mg dose. From
baseline to week 52, mean changes in vdH-mTSS
were 1.66 and 2.21 for the secu-
kinumab 150 mg and 75 mg groups, respectively.
From baseline to week 104, mean changes in
vdH-mTSS were 3.83 and 5.58 for the secu-
kinumab 150 mg and 75 mg groups, respectively.
Safety
Short Term Placebo-Controlled Period (to
Week 16)
During the first 16 weeks, AEs were reported at a
similar frequency across all treatment groups,
with 54.5% and 58.1% of patients in the secu-
kinumab 150 mg and 75 mg groups experiencing
an AE, respectively, compared with 57.0% of
patients in the placebo group (Table 3).
The most frequently reported treat-
ment-emergent AEs (TEAEs) by system organ
class were infections and infestations (23.5%
and 28.6% in the secukinumab 150 mg and
75 mg groups, respectively, compared with
25.2% in the placebo group), gastrointestinal
disorders (10.3% and 11.4% compared with
16.8%), and musculoskeletal and connective
tissue disorders (9.4% and 8.6% compared with
15.0%) (Table 3). Nasopharyngitis, pharyngitis,
bronchitis, upper respiratory tract infection and
headache were the most frequently reported
TEAEs in the any secukinumab group up to
Fig. 2 ACR20 response using non-responder imputation
over 24 weeks. Symbols indicate P B 0.05. *P\0.05 for
secukinumab 150 mg vs placebo; P\0.05 for secu-
kinumab 75 mg vs placebo. P values are adjusted for
multiplicity of testing for secukinumab 150 mg and
secukinumab 75 mg vs placebo at week 24. ACR American
College of Rheumatology, ACR20 improvement of C 20%
in ACR disease activity, IV intravenous, n number of
subjects randomized
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week 16. The majority of AEs reported up to
week 16 in the any secukinumab dose group
were mild (31.4%) or moderate (19.6%) in
severity.
SAEs were reported for a higher percentage of
patients in the any secukinumab group (4.5%)
compared with the placebo group (3.7%).
Infections and infestations qualifying as SAEs
were reported by 5 (1.9%) patients in the any
secukinumab group compared with three
patients (0.5%) in the placebo group. Gastroin-
testinal disorders were reported as SAEs by three
patients (1.4%) in the secukinumab 75 group
only. There were no reports of IBD. There were
no clinically meaningful differences in the
incidence of SAEs between the two
secukinumab groups.
Lower proportions of patients in the any
secukinumab dose group (2.8%) had TEAEs
leading to discontinuation from study treat-
ment compared with the placebo group (4.7%),
which was mainly driven by the higher inci-
dence of patients discontinuing treatment due
to RA in the placebo group (1.4% and 0.2%,
respectively).
In the placebo-controlled period up to week
16, one death was reported; a patient in the
placebo group who suffered cardiopulmonary
failure, with pneumonia as a contributing
factor.
Entire Treatment Period
The incidence of AEs during the entire treat-
ment period was comparable within the two
secukinumab groups (76.0% and 78.7% in the
any secukinumab 150 mg and 75 mg groups,
respectively). The most common reason for the
discontinuation was study discontinuation by
sponsor (25.4% and 22.4% in the any secu-
kinumab 150 mg and 75 mg groups, respec-
tively) followed by lack of efficacy (13.1% and
19.5%, respectively; supplementary Fig. S1).
Similar to the first 16 weeks of the study, AEs
over the entire treatment period in the any
secukinumab group were reported most fre-
quently in the SOCs infections and infestations
(55.6%), musculoskeletal and connective tissue
disorders (27.3%), and gastrointestinal disorders
(26.5%). No dose dependency in AEs in any
SOC was observed for secukinumab. Of TEAEs
by preferred term in the any secukinumab
group, nasopharyngitis, upper respiratory tract
infection, urinary tract infection, bronchitis
and RA were the most frequently reported
(Table 3). There were no clinically meaningful
differences in the incidence of AEs between the
two secukinumab regimens. The majority of AEs
reported in the any secukinumab dose group
during the entire treatment period were mild
(35.8%) or moderate (33.9%) in severity.
SAEs were reported for similar percentages of
patients in the any secukinumab 150 mg group
(12.2%) and the any secukinumab 75 mg group
(11.0%). The two most common SAEs in the any
secukinumab group during the entire treatment
period were infections and infestations [n = 30,
incidence rate (IR) 3.1 per 100 patient years]
and musculoskeletal and connective tissue dis-
orders (n = 15, IR 1.5 per 100 patient years).
There were no clinically meaningful differences
in the incidence of SAEs between the two
secukinumab groups.
Similar proportions of patients in the any
secukinumab 150 mg and 75 mg groups (5.6%
and 4.3%, respectively) discontinued treatment
due to TEAEs (Table 3). There were no clinically
meaningful differences in the proportions of
patients with potential compound- and
class-related risks based on AEs in both secu-
kinumab groups.
The exposure-adjusted incidence rate (EAIR)
of adjudicated major adverse cardiovascular
events (MACE) in the any secukinumab group
was 0.5 per 100 patient years. The EAIR for
neutropenia in the any secukinumab group was
1.3 per 100 patient years. The EAIR for fungal
infections in the any secukinumab group was
3.5 per 100 patient years.
Treatment emergent anti-drug antibodies
(ADAs; developing on secukinumab treatment
in patients negative at baseline) were detected
for 38 patients. Neutralizing antibodies were
not detected in any patients. Of the 38 patients
with treatment emergent ADAs, 28 had
detectable ADAs at single time points, while
ADAs were detectable at more than one time
point in only 10 patients.
Five deaths occurred after week 16; two in
the any secukinumab 150 mg group (due to
sepsis and myocardial infarction), and three in
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the any secukinumab 75 mg group (one due to
acute myocardial infarction, one due to inter-
stitial lung disease, and one of unknown cause).
Over the entire treatment period, a total of 6
deaths were reported: 2 in the secukinumab
150 mg group, 3 in the any secukinumab 75 mg
group, and 1 in the placebo group.
DISCUSSION
The treatment of RA continues to evolve and
the potential role of IL-17 inhibition in the
management of this disease remains an impor-
tant issue. This phase 3 trial presents the only
formal study of the effect of IL-17A inhibition
on structural progression in patients with RA.
Based on pre-defined hierarchical testing the
primary endpoint was met by both the 150 mg
and 75 mg secukinumab dose groups, indicat-
ing a statistically superior treatment effect over
placebo. However, the main secondary objec-
tive (HAQ-DI at week 24) was not met for either
secukinumab dose. A numerical reduction in
radiographic progression was observed for the
pooled secukinumab doses vs placebo in the
placebo-controlled period of 24 weeks, but fell
short of meeting statistical significance as
pre-defined in the hierarchical testing. The
protocol mandated escape of placebo patients
to secukinumab after week 16, and more than
half the placebo patients switched to secu-
kinumab at that time. This means that there
was only a very short period during which
radiographic progression on placebo could be
captured given this placebo-controlled trial
design.
Results from the phase 3 NURTURE trial, that
directly compared secukinumab with abatacept
in RA [19], as well as indirect comparisons of the
efficacy from this trial with the efficacy of bio-
logics approved for use in patients for whom
TNF-inhibitors have failed, suggest that IL-17A
inhibition offers no additional benefit to RA
patients with inadequate response to TNF-in-
hibitors over currently approved therapies
[20, 21]. These findings led to a decision to
discontinue the present trial, which bore influ-
ence on discontinuation rates in the core part of
this trial (up to week 104), meaning that no
patient completed the long-term extension. Of
the 637 patients randomized, only 237 (37.2%)
completed 104 weeks of treatment. The most
frequent reasons for study discontinuation were
termination by sponsor (23.1%) and lack of
efficacy (16.6%). Therefore, any conclusions, in
particular on the longer-term efficacy out-
comes, are very limited.
Safety data from this trial confirmed the
safety profile of secukinumab as seen in the
phase 3 trials in psoriasis [10], PsA [12] and AS
[13]. The overall safety profiles of the secu-
kinumab 150 mg and secukinumab 75 mg dose
groups in this study were similar, with
nasopharyngitis, upper respiratory tract infec-
tion, urinary tract infection, bronchitis and RA
being most frequently reported TEAEs with
secukinumab during entire treatment period.
EAIRs for MACE [22] and deaths [23] are com-
parable to those observed for other biologics in
patients with RA.
CONCLUSIONS
In summary this phase 3 trial is the only study
of IL-17A inhibition on structural progression in
RA. While there may have been a numerical
trend for inhibition of structural progression
the trial was hampered by high discontinuation
rates and a very short placebo period. In con-
trast to the good efficacy of IL-17A inhibition
seen in psoriasis, PsA and AS, secukinumab is of
lesser benefit in RA patients for whom TNF-in-
hibitor therapy has failed. Given that multiple
biologics with good efficacy are already avail-
able to these patients, further development of
secukinumab for RA patients was not pursued.
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